2 Growth Stocks to Hold for the Next Decade

Shares of Intuitive Surgical are down 13% and DexCom down 12% over the trailing 12 months, but both companies retain multi-year growth optionality. Intuitive faced tariff-related hits in 2025 and new U.S. competition from Medtronic's Hugo (urology), yet it has an installed base of 11,106 da Vinci systems, pricing power to offset tariffs, and an aging-population-driven procedure tailwind. DexCom had limited CGM receiver recalls but serves ~3.5M patients globally with an addressable U.S. insurance-covered pool of >9M nonusers; its OTC Stelo (cleared 2024) has >500k users and targets a U.S. population with >40% prediabetes, indicating a large growth runway.

Analysis

The durable economics in both franchises come from high-margin recurring revenue and embedded switching costs that lengthen payback on installed capital; that creates a two- to five-year optionality window where service, consumables, and upgrade cadence drive free cash flow more than unit shipments alone. Expect upstream suppliers (precision motors, optics/vision stacks, sterile consumable manufacturers) to see revenue growth and pricing leverage ahead of OEM margin recovery — these supply-chain firms can signal durable end-market strength months before OEMs print it.

Key near-term reversal risks are policy or reimbursement shifts and episodic product-quality headlines that compress adoption velocity; these act quickly (days–weeks) on sentiment but take quarters to flow through backlog/installation metrics. Conversely, multi-year outperformance requires persistent expansion of non-traditional end users and successful conversion of insured-but-untapped cohorts; trackable catalysts are quarterly installation/usage cadence and incremental reimbursement approvals that unlock larger payer pools.

Tactically, asymmetric option structures capture the optionality while limiting capital at risk: LEAP call spreads hedge time decay versus outright calls, and short-dated hedges protect against headline risk while leaving long-dated upside intact. For allocators, size positions to no more than 3–5% of liquid equity exposure per name and stagger entries around installation data and next two quarterly reports to avoid buying into pre-announcement volatility.

The consensus underweights the annuity-like margin lift from consumables and service upgrades and simultaneously overestimates the pace at which new competitors can convert entrenched customers. That gap creates a multi-year convex payoff if installation growth re-accelerates and pricing power is modestly exercised, but it is balanced by genuine regulatory and consumer-adoption execution risk that merits disciplined hedging.

Key Decisions for Investors

• Long ISRG LEAP call spread: buy Jan 2028 LEAPS (lower strike) and sell higher strike to fund position — target 18–30 month horizon; size 2–3% NAV. R/R: limited premium risk (~max loss = premium) for >2x upside if installation/attach-rate inflection occurs within 24 months.
• Long DXCM via staggered call spreads: initiate 2 tranches of 12–30 month call spreads to express secular adoption into broader populations while capping cost. Risk: premium at risk if consumer uptake stalls; Reward: 2–4x upside if adoption and recurring revenue scale as modeled.
• Pair (idiosyncratic hedge): long ISRG equity (or LEAPs) vs small-sized short of a cycle-sensitive competitor (MDT) — size short at 25–33% of long notional. Timeframe 12–24 months. This expresses share-price leadership in the niche while limiting exposure to broad medtech selloffs.
• Protection trade: buy 6–12 month puts (~5–8% notional) on core positions around major data/Revenues prints to guard against rapid sentiment shocks from regulatory or product-quality headlines. Cost is insurance against >15–20% drawdowns in a name.